

FABRIZIO ANGIUS

Curriculum Vitae et Studiorum

ORCID: <http://orcid.org/0000-0001-6613-603X>
Scopus: <https://www.scopus.com/authid/detail.uri?authorId=23479266600>
Researchgate: https://www.researchgate.net/profile/Fabrizio_Angius/info

ESPERIENZE LAVORATIVE E DI RICERCA

Nov 2023 – oggi Professore Associato, Microbiologia e Microbiologia Clinica, UniCa (IT)
Ott 2024 - Nov 2024 Visiting Professor, Dipartimento di Pediatria e Malattie Infettive, Columbia University New York (US)
Nov 2020 – Ott 2023 Ricercatore TDb, Microbiologia e Microbiologia Clinica, UniCa (IT)
Lug 2019 – Ott 2020 Borsista di ricerca, *Approcci innovativi per il monitoraggio, la diagnosi e gli obiettivi terapeutici nelle malattie neuroinfiammatorie e neurodegenerative*, UniCa (IT)
Set 2019 – Dic 2019 EMBO-ST-Fellow, *Applicazione rivoluzionaria di un innovativo modello animale di infezione da virus chimera per studiare l'effetto curativo dei derivati sulfonamidici contro le neoplasie indotte da gamma-Herpesvirus*, Instituto de Microbiologia, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbona (PT)
Nov 2018 - Mar 2019 Borsista di ricerca, *Sviluppo di antivirali per patogeni emergenti*, UniCa (IT)
Feb 2016 - Set 2017 Ricercatore post-dottorato senior, *Ricerca applicata nel campo delle malattie infettive pediatriche focalizzata sui meccanismi di ingresso e fusione delle membrane mediate dai Paramyxovirus*, Dipartimento di Pediatria e Malattie infettive, Columbia University New York (USA)
Apr 2016 - Lug 2016 Borsista di ricerca, *Sviluppo di antivirali per i patogeni emergenti Ebola e Marburg. Creazione di una piccola libreria di molecole naturali e nuovi composti sintetici con attività antivirale*, finanziata dalla Cornell University, New York (USA)
Lug 2014 - Lug 2015 Assegnista di ricerca, *Valutazione della potenziale tossicità di leghe di nanopolveri a basso punto di fusione esenti da piombo*, UniCa (IT)
Mag 2014 - Giu 2014 Ricercatore in visita, Università di Konstanz (DE)
Apr 2013 - Set 2013 Borsista di ricerca, *Studio dei meccanismi attraverso cui le infezioni possono causare la malattia vascolare aterosclerotica in soggetti sani o aggravarla in pazienti con diabete mellito*, UniCa (IT)
Gen 2013 - Giu 2013 Borsista di ricerca, *Sviluppo di nuovi metodi di screening diagnostico e riabilitazione funzionale per la medicina preventiva*, finanziato da UniCa e RGMD (IT)
Mag 2010 - Mag 2012 Responsabile scientifico, *Metabolismo del colesterolo e malattia di Alzheimer: ulteriori sviluppi sugli aspetti biochimici e molecolari delle cellule mononucleate del sangue e dei fibroblasti cutanei nella popolazione sarda*, finanziato dalla Regione Autonoma della Sardegna (RAS)
Feb 2007 - Gan 2010 Dottorando in Scienze Morfologiche presso UniCa (IT)
Mar 2006 - Ago 2007 COnsultante di laboratorio, Cagliari (IT)
Set 2005 - Feb 2006 Tirocinio post-laurea, *Autosomministrazione di cannabinoidi nei ratti: differenze di sesso e influenza della funzione ovarica*, Dip. di Neuroscienze, UniCa (IT)
Ott 2004 - Lug 2005 Tirocinio pre-laurea, Dipartimento di Neuroscienze, UniCa (IT)

EDUCATION

- Set 2015** Summer School: *Malattie neurodegenerative da prioni e prioni-simili* (Cagliari)
- Gen 2010** Dottorato di Ricerca in Scienze Morfologiche, UniCa (IT)
Tesi: *Dati preliminari mediante metodi di imaging sulle variazioni del colesterolo intracellulare nella malattia di Alzheimer* (ottimo feedback) - Supervisore: Prof G Diaz
- Nov 2005** Abilitazione Biologo, Esame di Stato presso UniCa (punteggio: 30/30)
- Lug 2005** Laurea in Scienze Biologiche 110/110 e lode presso l'UniCa
Tesi: *Ruolo differente del recettore cannabinoide CB1 e degli oppioidi nei meccanismi di ricaduta all'abuso di eroina* - Relatore: Prof. W Fratta
- Lug 1999** Diploma di scuola superiore presso l'Istituto Salesiano San Giovanni Bosco (Cagliari)

ESPERIENZA DI INSEGNAMENTO E QUALIFICAZIONE

- 2023-oggi** MEDS-03/A, Microbiologia e Virologia, Odontoiatria, Facoltà di Medicina (UniCa)
- 2023-oggi** MEDS-03/A, Microbiologia Clinica Generale, Medicina e Chirurgia, Facoltà di Medicina (UniCa)
- 2023-oggi** MEDS-03/A, Scuola di Specializzazione Igiene e Medicina Preventiva (UniCa)
- 2022-oggi** MEDS-03/A, Microbiologia, Facoltà di Biologia e Farmacia (UniCa)
- 2020-oggi** MEDS-03/A, Scuola di Specializzazione Microbiologia e Virologia (UniCa)
- 2020-oggi** MEDS-03/A, Microbiologia Clinica Generale, Infermieristica, Facoltà di Medicina e Chirurgia (UniCa)
- 2019-2020** MEDS-03/A, Supporto alla didattica in Microbiologia (UniCa)
- 2019-oggi** Abilitazione Scientifica Nazionale Professore Associato in Microbiologia e Microbiologia Clinica (06/A3-MEDS-03/A), Ministero dell'Istruzione, dell'Università e della Ricerca (MIUR)
- 2017-oggi** Cultore della materia, Microbiologia e Microbiologia Clinica MEDS-03/A (UniCa)
- 2016-2017** MEDS-03/A, Supporto alla didattica in Microbiologia (UniCa)
- 2015-2016** MEDS-03/A, Supporto alla didattica in Microbiologia (UniCa)
- 2018-2019** Insegnante di Matematica e Scienze (Scuola Secondaria di I grado, Cagliari)
- 2009-2010** Tutor accademico, Facoltà di Medicina (UniCa)

INCARICHI ACCADEMICI

- 2024-oggi** **Coordinatore Erasmus**, Facoltà di Medicina (UniCa)
- 2024-oggi** **Consiglio didattico** Corso di Laurea Scienze tossicologiche e garanzia della qualità, Facoltà di Biologia e Farmacia (UniCa)
- 2024-oggi** **Commissione Ricerca e VQR**, Dipartimento Scienze Biomediche (UniCa)
- 2023-oggi** **Collegio dei docenti** Scuola di Specializzazione Igiene e Medicina Preventiva (UniCa)
- 2020-date** **Collegio dei docenti** Scuola di Specializzazione Microbiologia e Virologia (UniCa)

SUPERVISIONE E MENTORING

- 2025-oggi** **Supervisore**, specializzandi non medici (Andrea Pibiri)
- 2025** **Supervisore**, tirocinio Daniela Tommainu (UniCa)
- 2025** **Supervisore**, tirocinio Valentina Scanu (UniCa)
- 2025** **Relatore**, Tesi triennale Valentina Agus (UniCa)
- 2024** **Supervisore**, tirocinio Maura Alessia Perra (UniCa)
- 2024** **Supervisore**, tirocinio Valentina Agus (UniCa)
- 2024** **Co-Relatore** Tesi triennale Chiara Mariotti (UniCa)
- 2024-oggi** **Supervisore**, tirocinante Andrea Pibiri (UniCa)
- 2024-oggi** **Supervisore**, specializzandi non medici (Serena Canton)
- 2024** **Relatore**, MD Tesi Silvio Zaimi (UniCa)

- 2024** **Relatore**, Tesi triennale Marco Pitzalis (UniCa)
- 2024** **Supervisore**, tirocinante Marco Pitzalis (UniCa)
- 2023** **Co-Relatore**, Tesi specialistica Giada Cannas (UniCa)
- 2023** **Co-Relatore**, MD tesi Piergiorgio Concu (UniCa)
- 2023** **Relatore**, Tesi triennale Elisa Raga (UniCa)
- 2024** **Supervisore**, tirocinante Elisa Raga (UniCa)
- 2023** **Co-Relatore**, Tesi triennale Edith Zedde (UniCa)
- 2022-23** **Supervisore**, borsisti (Ilenia Delogu, Vanessa Palmas)
- 2021-oggi** **Supervisore**, specializzandi medici (Silvia Puxeddu, Giuseppe Pala)
- 2020** **Co-Relatore**, Tesi triennale Nicola Ciabatti (UniCa)
- 2019** **Co-Relatore**, Tesi Tania Rodrigues (University of Lisbon, PT)
- 2018** **Co-Relatore**, Tesi Sara Armas (UniCa)

CERTIFICAZIONE FORMATIVA

- 2024** Formazione sulla sicurezza biologica/patogeni trasmessi dal sangue (Columbia University, NY, USA)
- 2024** Primo Soccorso (Cagliari, IT)
- 2024** BLS (Cagliari, IT)
- 2021** Salute, sicurezza e rischi specifici sul lavoro (Cagliari, IT)
- 2020** BSL3
- 2018** English Language (B2 level)
- 2018** Salute e sicurezza sul lavoro (Cagliari, IT)
- 2017** Formazione sull'uso sicuro della formaldeide (Columbia University, NY, USA)
- 2017** Spedizione di materiali biologici (infettivi e potenzialmente infettivi) e microrganismi geneticamente modificati (OGM) (Columbia University, NY, USA)
- 2017** Spedizione con ghiaccio secco, campioni esenti e quantità esenti di merci pericolose (Columbia University, NY, USA)
- 2017** Formazione sperimentazione animali roditori (Columbia University, NY, USA)
- 2017** Formazione sulla cappa e sicurezza biologica (Columbia University, NY, USA)
- 2016** Sperimentazione animale, topi e ratti (Columbia University, NY, US)
- 2016** Sicurezza di laboratorio, igiene chimica e gestione dei rifiuti pericolosi (Columbia University, NY, USA)
- 2016** Laboratorio sui topi (Columbia University, NY, USA)
- 2016** Introduzione all'Istituto di Medicina Comparata (Columbia University, NY, USA)
- 2013** Corso di formazione in radioprotezione (UniCa, IT)
- 2013** Business English Certificate (University of Cambridge, UK)

COMPETENZE E INTERESSI

- Lingue** Italiano e Inglese
- Interessi** Musica - Fotografia - Lettura - Viaggi
- IT** Office - editing audio, video e imaging - OS Microsoft and iOS

PREMI

- 2024** **Young Research Mobility Program**, Columbia University (NY, US), Focus sulla progettazione di un nuovo set di prodotti biologici su misura per virus adattati al sistema nervoso centrale, RAS L7/2007 (IT)
- 2019** **Sigillo di eccellenza**, [VirGenEra] Applicazione rivoluzionaria di un innovativo modello animale di infezione da virus chimera per studiare l'effetto curativo dei derivati sulfonamidici contro le neoplasie indotte da gamma-Herpesvirus, Commissione europea, Bruxelles (BE)

- 2018** **AMCLI Educational Grant**, *Ruolo del laboratorio di microbiologia nell'applicazione del piano nazionale di prevenzione vaccinale per pertosse, morbillo, rosolia, parotite e varicella*. AMCLI, Cagliari (IT), 7 dicembre 2018
- 2018** **FEMS Travel Grant**, Virus del morbillo e adattamento, 46° Congresso Nazionale SIM, Palermo (IT), 26-29 settembre 2018
- 2017** **Premio Fondazione Mario Campa per il miglior poster in virologia**, *Infezione del morbillo nel sistema nervoso centrale e sua inibizione*, 45° Congresso Nazionale SIM, Genova (IT), 27-30 settembre 2017
- 2013-oggi** **Personale contrattuale di Europe Research (agenti contrattuali FG IV)**, candidato n. 3557361, selezionato come ricercatore CAST idoneo presso il JRC e le agenzie dell'UE tramite selezione europea EPSO/CAST/S/5/2013
- 2013** **2° Miglior Poster in Virologia**, *Lipidi neutri e angiogenesi in cellule primarie umane infette con herpes virus 8*, 41° Congresso Nazionale SIM, Riccione (IT), 13-16 ottobre 2013
- 2008** **Best Poster Prize**, *Cardiovascular disease in β -thalassemia intermedia: involvement of cholesterol and iron metabolism*, 5th National Congress SoSTE, Cagliari (IT), 16-18 Oct 2008

BORSE DI STUDIO E PARTECIPAZIONI A PROGETTI DI RICERCA

- 2024** **Principal Investigator**, *[MIMOSA] Valutazione dello stato di MicrobioMe e redOx plasmatico nelle donne con tumore al seno: uno studio preliminare sulla potenziale associazione con il consumo di alcol*, Fondazione di Sardegna 2022 (IT)
- 2024** **Partecipante**, *[PROFILES] Peripheral and cenRal Immune prOFiles revealing the Impact of sex on biomarkers in muLtiplE sclErosis and parkinSon's disease*, PNRR Cascade Open Call MNESYS Spoke 7, Neuroimmunology and Neuroinflammation (IT)
- 2023** **Associate investigator**, *[NEMESI] One Development of New MEmbranes as Smart devices to limit Infections*, PRIN 2022CAWK8W (IT)
- 2022** **Partecipante**, *[INF-ACT] One Health Basic and Translational Research Actions addressing Unmet Needs on Emerging Infectious Diseases*, PNRR PE0000007 Emergent Malattie infettive (IT)
- 2022** **Ricercatore associato**, *[RiV4PoC] Rivestimento microbicide per superfici ad alto contatto*, Sardegna Ricerche, RAS (IT)
- 2022** **Ricercatore associato**, *[f-PERMEATE] Funzione predittiva del coefficiente di permeabilità dei farmaci per lo screening di grandi database*, Sardegna Ricerche, RAS (IT)
- 2022** **Ricercatore associato**, *Alcol e altri fattori di rischio modificabili per il cancro al seno*, [35781] Fondazione di Sardegna (IT)
- 2020** **Partecipante**, *[Coating4CoV] Rivestimento con proprietà antivirali per dispositivi medici, superfici e oggetti ad alto contatto in luoghi pubblici*, SR4COVID, Sardegna Ricerche, RAS (IT)
- 2019** **EMBO-STF Grant**, *Applicazione rivoluzionaria di un innovativo modello animale di infezione da virus chimera per studiare l'effetto curativo dei derivati sulfonamidici contro le neoplasie indotte da gamma-Herpesvirus*, EMBO Excellence in Science, Heidelberg (DE)
- 2019-oggi** **Collaboratore**, *Approcci innovativi per monitoraggio, diagnosi e target terapeutici nelle malattie neuroinfiammatorie e neurodegenerative*, UniCa (IT). PI: Prof A Ingianni, Prof AR Carta
- 2018-2019** **Collaboratore**, *Sviluppo di antivirali per patogeni emergenti*, UniCa (IT). PI: Prof A Ingianni
- 2017-oggi** **Collaboratore** nell'area delle infezioni latenti focalizzato specificamente sui gamma-Herpesvirus, sviluppo di antivirali per patogeni emergenti, studio sull'attività terapeutica di composti sulfonamidici per l'eliminazione dell'herpes virus umano 8 dal

sarcoma di Kaposi infettato in modo latente. UniCa, Lineberger Comprehensive Cancer Center, Center for AIDS Research, University of North Carolina at Chapel Hill (NC, USA), Institute of Molecular Medicine (iMM) e Institute of Microbiology, University of Lisbon (PT)

- 2016-oggi Collaboratore** nell'area delle malattie infettive pediatriche specificamente focalizzato sui meccanismi di ingresso e fusione delle membrane mediati dai Paramyxovirus, Columbia University (New York, NY)
- 2016-2017 Collaboratore**, *Alterazioni del metabolismo lipidico nelle cellule umane infettate dal virus Herpes 8: implicazioni nelle alterazioni metaboliche che predispongono alla comparsa del diabete mellito di tipo 2*. PI: Prof R Pompei
- 2015-2018 Collaboratore**, *Nuovi farmaci neuroprotettivi per la malattia di Parkinson e ruolo della neuroinfiammazione nello sviluppo di discinesie indotte da L-DOPA*, supportato da Fondazione Banco di Sardegna e Perry & Ruby Stevens Charitable Foundation. PI: Prof AR Carta
- 2013-2014 Collaboratore**, *Alterazioni del metabolismo lipidico in cellule umane infettate da Herpes virus 8: implicazioni nelle alterazioni metaboliche che predispongono alla comparsa del diabete mellito di tipo 2*. PI: Prof R Pompei
- 2010-2012 Principal Investigator**, *Metabolismo del colesterolo e malattia di Alzheimer: ulteriori sviluppi sulle basi biochimiche e molecolari delle cellule mononucleate del sangue e dei fibroblasti cutanei nella popolazione sarda*, Grant CRP2_151 finanziato da RAS L7/2007
- 2011-2012 Collaboratore**, *Alterazioni del metabolismo del glucosio e dei lipidi in cellule infettate da Herpes virus 8 e metodi di interferenza con l'espressione virale*, finanziato da FBS. PI: Prof R Pompei
- 2011 Collaboratore**, *Sviluppo di nanostrutture magnetiche composite biocompatibili*, Progetto di ricerca di base e orientata finanziato da RAS. PI: Dr C Cannas
- 2008 Collaboratore**, *nanoparticelle superparamagnetiche ibride per il rilascio di molecole funzionali guidate da campi magnetici e ligandi in superficie*, finanziato da RAS L7/2007. PI: Prof G Piccaluga
- 2007 Collaboratore**, *nanoparticelle magnetiche ibride per il trasporto di biomolecole mediante campi magnetici esterni*, PI: Dr C Cannas

PATENTS

- 2021** [WO2021255496A1](#) Rivestimento antibatterico, Scano A, Ennas G, Esposito F, Tramontano E, ANGIUS F (UniCa, IT)

PRESENTATIONS

- Set 2024 Poster**, Implementing an effective microbicidal coating to tackle indirect microbial transmission. National Congress SIM, Pavia (IT), 8-11 Sep 2024
- Lug 2024 Poster**, Preliminary data on KSHV integration in humans: a potential molecular mechanism for viral-induced oncogenesis? SIV-ISV, Bologna (IT), 22-24 Jul 2024
- Set 2023 Poster**, Sulfonamide treatments inhibit gamma-Herpesvirus persistent infection in vivo. National Congress SIM, Cagliari (IT), 24-27 Sep 2023
- Set 2022 Poster**, *RiV4PoC: A high effective microbicidal coating for high-touch surfaces*. 50th National Congress SIM, Naples (IT), 18-21 Sep 2022
- Set 2020 Poster**, *Characterization of a measles virus neutralizing monoclonal antibody targeting specific conformation of fusion protein*. 48th Virtual National Congress SIM, 21-22 Sep 2020
- Set 2019 Poster**, *Functional analysis of a SSPE virus indicates that hyperfusogenic fusion protein contributes to measles virus infection in the brain*. 47th National Congress SIM, Rome (IT), 18-21 Sep 2019
- Set 2019 Poster**, *Human Herpesvirus 8 infection contributes to ROS production in diabetes type 2 patients*. 47th National Congress SIM, Rome (IT), 18-21 Sep 2019

- Set 2018** **Poster**, *Measles virus and CNS adaptation*. 46th National Congress SIM, Palermo (IT), 26-29 Sep 2018
- Set 2017** **Poster**, *Measles CNS infection and its inhibition*. 45th National Congress SIM, Genoa (IT), 27-30 Sep 2017
- Set 2015** **Invited Speaker**, *Herpesvirus 8 infection and cellular metabolism alterations*, 43rd National Congress SIM, Naples (IT), 27-30 Sep 2015
- Set 2015** **Poster**, *Sulfonamide compounds inhibit latent Human Herpesvirus 8 replication by interfering with MDM2-p53 complex formation*. 43rd National Congress SIM, Naples (IT), 27-30 Sep 2015
- Mar 2015** **Invited Speaker**, *Role of P-gp in controlling of metabolism in MDR1 cells: HDL as new delivery strategy for anticancer drugs*, Riunione Scientifica Scuola Mario Umberto Dianzani, Cagliari (IT) 20-21 Mar 2013
- Set 2014** **Poster**, *Anti Human Herpesvirus 8 antibodies regulate the metabolic modifications induced by viral infection on primary endothelial cells*. 42nd National Congress SIM, Torino (IT), 28 Sept – 01 Oct 2014
- Giu 2014** **Poster**, *Inhibition of cholesterol esterification increases cholesteryl ester uptake from HDL in parental and MDR1 resistant CCRF-CEM cells*. European Association for Cancer Research (EACR), American Association for Cancer Research (AACR), Italian Cancer Society (SIC) Special Conference, Florence (IT), 20-23 June 2014
- Ott 2013** **Poster**, *Lipidi neutri e angiogenesi in cellule primarie umane infettate con virus Herpes 8*. 41st National Congress SIM, Riccione (IT), 13-16 Oct 2013
- Mar 2012** **Poster**, *Neutral lipids accumulation in peripheral blood mononuclear cells: hallmark of Alzheimer's Disease?* 6th World Congress on Controversies in Neurology (CONy), Wien (AT), 8-11 Mar 2012
- Mar 2012** **Poster**, *Alteration of intracellular cholesterol in skin fibroblasts from Alzheimer's Disease patients*. 6th World Congress on Controversies in Neurology (CONy), Wien (AT), 8-11 Mar 2012
- Nov 2008** **Invited Speaker**, *Role of lipid metabolism in Alzheimer's Disease: morphological studies in peripheral cells*. 53rd National Congress SIGG, Firenze (IT), 26-29 Nov 2008

MEMBERSHIP

- 2023 - oggi** ASV (American Society for Virology)
- 2018 - oggi** ASM (American Society for Microbiology)
- 2017 - oggi** US National Postdoctoral Association
- 2015 - oggi** EURODOC (European Council of Doctoral Candidates and Junior Researchers)
- 2015 - oggi** ADI (National PhD and PhD Students Association in Italy)
- 2019 - 2020 Vice-coordinator** ADI Cagliari
- 2013 - oggi** FEMS (Federation of Microbiological Societies)
- 2013 - oggi** ESCMID (European Society of Clinical Microbiology and Infectious Diseases)
- 2013 - oggi** SIM (Italian Society of Microbiology)
- 2006 - oggi** Professional National Order of Biologists (ID 056586)

COMITATO EDITORIALE E REVISIONE

- **Associate Editor:** *Frontiers in Molecular Diagnostics and Therapeutics*
- **Chairman:** Primary prevention of breast cancer: A UniCA proposal, Round table "Collaborating to prevent", 18 Oct 2023, UniCa
- **Topic Editor:** *Host Response against SARS-CoV-2 Infection: Implications for Diagnosis, Treatment and Vaccine Development*. MDPI (Antibodies, COVID, Pathogens, Vaccines, Viruses) [link](#)
- **Reviewer Editor:** *Frontiers in Virology*

- **Reviewer Board:** Cells (MDPI)
- **Editorial board:** Viruses (MDPI), International Scholarly Research Notices (Hindawi)
- **Reviewer:** Vaccines; Molecules; Biomolecules; Antioxidants; Oncotarget; BioTechniques; International Journal of Pharmaceutics; International Journal of Molecular Sciences; Journal of Infectious Diseases in Developing Countries; Journal of Cellular and Molecular Medicine; Journal of Clinical Laboratory Analysis; Toxicology Mechanisms and Methods; Medical Research Archives
- **Chapter:** Pompei R, **ANGIUS F** (2021) Capitolo 42, *Batteri patogeni di incerta collocazione*, in *Microbiologia Farmaceutica*. III ed, EdiSES (ISBN: 9788836230211)
- **Chapter:** **ANGIUS F**, Marras L, Ingianni A, Pompei R. *Latent-persistent Virus Infections. Hepatitis C Virus and Human Herpesvirus 8: Immunological Response, Modification of Cell Metabolism and Association with Type 2 Diabetes*. Book Emerging and Re-emerging Viral Pathogens, Elsevier
- **Chapter:** Piras E, Madeddu MA, Palmieri G, **ANGIUS F**, Contini P, Pompei R, Ingianni A (2016) *High Prevalence of Human Herpesvirus 8 Infection in Diabetes Type 2 Patients and Detection of a New Virus Subtype*. Adv Exp Med Biol.
- **Committee:** Ricerca in Vetrina 2018 - **ANGIUS F**, Leccis F, Mei G, Mura E (2018) *Sviluppo, Risorse e Ambiente*, in Lai L, Mastinu M, Saiu V (a cura di), Ricerca in Vetrina 2018. Ricerca e democrazia. FrancoAngeli, Milano (IT). ISBN: 9788891772152 - 9788891783806
- **Committee:** Ricerca in Vetrina 2015 - **ANGIUS F**, Schirru MS (2015) *Science, Culture, and Economy of Food*, in Lai L, Mastinu M, Saiu V, Schirru MS (a cura di), Ricerca in Vetrina 2015. PhD in Sardinia: Higher Education, Scientific Research and Social Capital. FrancoAngeli, Milano (IT). ISBN: 9788891736635

PUBBLICAZIONI

1. **ANGIUS F**, Bigi R, Puxeddu S, Delogu I, Pompei R, Dittmer DP, Manzin A. *Inhibition of gamma-herpesvirus latent infection in an innovative chimera-virus animal model by sulfonamide antibiotics*. J Ant Chem (submitted)
2. Boi S, Puxeddu S, Delogu I, Farci D, Piano D, Manzin A, Ceccarelli M, **ANGIUS F***, Scorciapino MA*, Milenkovic S. *Seeking correlation among porin permeabilities and minimum inhibitory concentrations through machine learning: a promising route to the essential molecular descriptors*. Molecules (submitted)
3. Puxeddu S, Viridis V, Sacco D, Depau M, Atzei AM, Pisano L, Di Rosa M, Vacquer S, Accardi G, Cirio EM, Manzin A, Marinelli C, **ANGIUS F**. *A case of stroke as a unique sign of subclinical infective endocarditis by Abiotrophia defectiva: a case report*. Int J Emerg Med 18, 17 (2025). <https://doi.org/10.1186/s12245-025-00814-6>
4. **ANGIUS F**, Puxeddu S, Zaimi S, Canton S, Sepher Nematollahzadeh, Pibiri A, Delogu I, Alvisi G, Moi ML, Manzin A. *SARS-CoV-2 evolution: Implications for Diagnosis, Treatment, Vaccine Effectiveness and Development*. Vaccines 2025, 13, 17. <https://doi.org/10.3390/vaccines13010017>
5. Sardu C, **ANGIUS F**, Contu P, Cosentino S, Deiana M, Frascini M, Madeddu C, Massa E, Mereu A, Minerba L, Politi C, Salis F, Sinclair JMA, Agabio R. *Raising awareness of alcohol as a modifiable risk factor for breast cancer: A randomized controlled trial comparing the efficacy of accessing an interactive website with a noninteractive website*. The Breast 2025, 79, 103868. DOI: <https://doi.org/10.1016/j.breast.2024.103868>
6. Vega-Benedetti AF, Porcedda C, Ercoli T, Fusco G, Burgaletto C, Pillai R, Palmas MF, Cantone AF, **ANGIUS F**, Solla P, De Simone A, Cantarella G, Giallongo C, Sogos V, Defazio G, Carta AR. *Immune responses to oligomeric α -synuclein in Parkinson's disease peripheral blood mononuclear cells*. J Neurol. 2024, Sep;271(9):5916-5929. DOI: <https://doi.org/10.1007/s00415-024-12554-3>
7. Puxeddu S, Scano A, Scorciapino MA, Delogu I, Vascellari S, Ennas G, Manzin A, **ANGIUS F**. *Physico-chemical investigation and antimicrobial efficacy of ozonated oils. The case study of commercial ozonated olive and sunflower seed refined oils*. Molecules 2024, 29, 679. DOI: <https://doi.org/10.3390/molecules29030679>
8. **ANGIUS F**, Mocchi I, Ercoli T, Loy F, Palmas MF, Cannas G, Manzin A, Defazio G, Carta AR. *Combined measure of salivary alpha-synuclein species as diagnostic biomarker for Parkinson's disease*. Journal of Neurology 2023, Nov;270(11):5613-5621. DOI: <https://doi.org/10.1007/s00415-023-11893-x>
9. Vascellari S, Orrù CD, Groveman B, Fenu G, Pisano G, Piga G, Serra G, Oppo V, Murgia D, Perra A, **ANGIUS F**, Manzin A, Cossu G, Caughey B. *α -Synuclein seeding activity in duodenum biopsies from*

10. Sanna G, Marongiu A, Firinu D, Piras C, Franci G, Galdiero M, Pala G, Palmas V, **ANGIUS F**, Littera R, Perra A, Orrù G, Campagna M, Costanzo G, Meloni F, Coghe F, Chessa L, Manzin A. *Neutralizing antibodies responses against SARS-CoV-2 in a Sardinian cohort group up to 9 months after BNT162b2 vaccination*. *Vaccines* 2022, 10, 531. DOI: <https://doi.org/10.3390/vaccines10040531>
11. Agabio R, Madeddu C, Contu P, Cosentino S, **ANGIUS F**, Deiana M, Massa E, Mereu A, Politi C, Sinclair J, Sardu C. *Alcol e tumore alla mammella*. *Alcologia* 2022, 48:60-70
12. **ANGIUS F**, Pala G, Manzin A. *SARS-CoV-2 and its variants: the pandemic of unvaccinated*. *Front. Microbiol.* 12:749634. 2021 Aug 24. DOI: <https://doi.org/10.3389/fmicb.2021.749634>
13. Mathieu C, Ferren M, Harder O, Bovier FT, Marcink TC, Predella C, **ANGIUS F**, Drew-Bear J, Dorrello NV, Greninger AL, Moscona A, Niewiesk S, Horvat B, Porotto M. *Single-chain variable fragment antibody constructs neutralize measles virus infection in vitro and in vivo*. *Cell Mol Immunol* 18, 1835–1837 (2021). DOI: <https://doi.org/10.1038/s41423-021-00691-y>
14. **ANGIUS F**, Ingianni A, Pompei R. *Human Herpesvirus 8 and host-cell interaction: long-lasting physiological modifications, inflammation and related chronic diseases*. *Microorganisms* 2020, 8(3), 388. DOI: <https://doi.org/10.3390/microorganisms8030388>
15. Incani A, Marras L, Serreli G, Ingianni A, Pompei R, Deiana M, **ANGIUS F**. *Human Herpesvirus 8 infection may contribute to oxidative stress in diabetes type 2 patients*. *BMC Res Notes* 13, 75 (2020). DOI: <https://doi.org/10.1186/s13104-020-4935-3>
16. **ANGIUS F**, Marras L, Ingianni A, Pompei R. *Latent-persistent Virus Infections. Hepatitis C Virus and Human Herpesvirus 8: Immunological Response, Modification of Cell Metabolism and Association with Type 2 Diabetes*. Book *Emerging and Re-emerging Viral Pathogens*, Elsevier. 2020 1:169-181. Available online 20 Sep 2019. DOI: <https://doi.org/10.1016/B978-0-12-819400-3.00009-0>
17. **ANGIUS F**, Smuts H, Rybkina K, Stelitano D, Eley B, Wilmshurst J, Ferren M, Lalande A, Mathieu C, Moscona A, Horvat B, Hashiguchi T, Porotto M, Hardie D. *Analysis of a subacute sclerosing panencephalitis (SSPE) Genotype B3 virus from the 2009/10 South African measles epidemic shows hyperfusogenic F proteins contribute to measles virus infection in the brain*. *J Virol.* 2019 Feb 5; 93(4). pii: e01700-18. DOI: <https://doi.org/10.1128/JVI.01700-18>
18. **ANGIUS F**, Piras E, Spolitu S, Marras L, Armas S, Ingianni A, Contini P, Pompei R. *Anti-Human Herpesvirus 8 antibodies affect both insulin and glucose uptake by virus-infected human endothelial cells*. *J Infect Dev Ctries*, 2018 June 12;6:485-491. DOI: <https://doi.org/10.3855/jidc.10381>
19. Lecca D, Janda E, Mulas G, Diana A, Martino C, **ANGIUS F**, Spolitu S, Casu MA, Simbula G, Boi L, Fenu S, Batetta B, Spiga S, Carta AR. *Boosting phagocytosis and anti-inflammatory phenotype in microglia mediates neuroprotection by PPAR γ agonist MDG548 in Parkinson's disease*. *Br J Pharm*, 2018 Mar. DOI: <https://doi.org/10.1111/bph.14214>
20. **ANGIUS F**, Madeddu MA, Pompei R. *Commentary: High glucose induces reactivation of latent Kaposi's Sarcoma-Associated Herpesvirus*. *Front Microbiol.* 2017 Sep 15;8:1796. DOI: <https://doi.org/10.3389/fmicb.2017.01796>
21. **ANGIUS F**, Piras E, Uda S, Madeddu C, Serpe R, Bigi R, Dittmer D, Ingianni A, Chen W, Pompei R. *Antimicrobial sulfonamides clear latent Kaposi Sarcoma Herpesvirus infection and impair MDM2-p53 complex formation*. *J Antibiot.* 2017 Aug; 70(9):962-966. DOI: <https://doi.org/10.1038/ja.2017.67>
22. Castangia I, Marongiu F, Manca M, Pompei R, **ANGIUS F**, Ardu A, Fadda AM, Manconi M, Ennas G. *Combination of grape extract-silver nanoparticles and liposomes: A totally green approach*. *Eur J Pharm Sci.* 2017 Jan 15; 97:62-69. DOI: <https://doi.org/10.1016/j.ejps.2016.11.006>
23. Piras E, Madeddu MA, Palmieri G, **ANGIUS F**, Contini P, Pompei R, Ingianni A. *High Prevalence of Human Herpesvirus 8 Infection in Diabetes Type 2 Patients and Detection of a New Virus Subtype*. *Adv Exp Med Biol.* 2017;973:41-51. DOI: https://doi.org/10.1007/5584_2016_73
24. Mulas G, Espa E, Fenu S, Spiga S, Cossu G, Pillai E, Carboni E, Simbula G, Jadžić D, **ANGIUS F**, Spolittu S, Batetta B, Lecca D, Giuffrida A, Carta AR. *Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous L-DOPA delivery in the 6-OHDA model of Parkinson's disease*. *Exp Neurol.* 2016 Sep 30. DOI: <https://doi.org/10.1016/j.expneurol.2016.09.013>
25. Spolitu S, Uda S, Deligia S, Frau A, Collu M, **ANGIUS F*** and Batetta B*. *Multidrug-resistance P glycoprotein dampens SR-BI cholesteryl ester uptake from high density lipoproteins in human leukemia cells*. *Am J Cancer Res.* 2016 Feb; 15;6(3):615-27. ISSN: 21566976
26. Carbonaro CM, Cannas C, Ricci PC, Orrù F, Ardu A, Corpino R, Chiriu D, **ANGIUS F**, Mura A. *Exploiting Dimer formation to achieve Superior Fluorescence Properties in Dye Doped Hexagonal Ordered Mesoporous Silica Nanoparticles*. *Microporous and Mesoporous Mat.* 2016. DOI: <https://doi.org/10.1016/j.micromeso.2016.01.028>

27. **ANGIUS F**, Spolitu S, Uda S, Deligia S, Frau A, Banni S, Collu M, Accossu S, Madeddu C, Serpe R, Batetta B. *High-density lipoproteins contribute to G0-G1/S transition in Swiss NIH/3T3 fibroblasts*. Sci. Rep. 2015; 5:17812. DOI: <https://doi.org/10.1038/srep17812>
28. Lacroix C, Laconi S, **ANGIUS F**; Coluccia A, Silvestri R, Pompei R, Neyts J, Leysen P. *In vitro characterisation of a pleconaril/pirodavir-like compound with potent activity against rhinoviruses*. Virol J. 2015 Jul 14; 12:106. DOI: <https://doi.org/10.1186/s12985-015-0330-4>
29. **ANGIUS F**, Madeddu MA, Pompei R. *Nutritionally Variant Streptococci Interfere with Streptococcus mutans Adhesion Properties and Biofilm Formation*. New Microbiol. 2015 Apr; 38(2):259-266. ISSN: 11217138
30. **ANGIUS F**, Uda S, Piras E, Spolitu S, Ingianni A, Batetta B, Pompei R. *Neutral lipid alterations in Herpes virus 8-infected HUVEC cells and their possible involvement in neo-angiogenesis*. BMC Microbiology. 2015 Mar 28; 15:74. DOI: <https://doi.org/10.1186/s12866-015-0415-7>
31. **ANGIUS F** and Floris A. *Liposomes and MTT cell viability assay: an incompatible affair*. Toxicol in Vitro. 2015 Mar; 29(2):314-9. Epub 2014 Dec 3. DOI: <https://doi.org/10.1016/j.tiv.2014.11.009>
32. **ANGIUS F**, Piras E, Deligia S, Frau A, Madeddu MA, Batetta B, Ingianni A, Contini P, Pompei R. *Anti-Human Herpesvirus 8 antibodies regulate the metabolic modifications induced by viral infection on primary endothelial cells*. New Microbiol. 37 (Suppl. 1) 1-202 (2014); ISSN: 11217138
33. **ANGIUS F**, Uda S, Spolitu S, Deligia S, Accossu S, Frau A, Batetta B. *Inhibition of cholesterol esterification increases cholesteryl ester uptake from hdl in parental and mdr1 resistant ccrf-cem cells*. Atherosclerosis 235 (2014) e192–e301. DOI: <https://doi.org/10.1016/j.atherosclerosis.2014.05.951>
34. Floris A, Fadda AM, Lai F, Marongiu F, Scano A, Pilloni M, **ANGIUS F**, Sinico C, Vázquez C. *Characterization and Cytotoxicity Studies on Liposome-Hydrophobic Magnetite Hybrid Colloids*. J Colloid Interface Sci. 2014 Mar. DOI: <https://doi.org/10.1016/j.jcis.2014.03.046>
35. Marongiu F, Serra MP, Sini M, **ANGIUS F**, Laconi E. *Clearance of senescent hepatocytes in a neoplastic-prone microenvironment delays the emergence of hepatocellular carcinoma*. Aging. 2014 Jan 23. DOI: <https://doi.org/10.18632/aging.100631>
36. Uda S, Spolitu S, **ANGIUS F**, Collu M, Accossu S, Banni S, Murru E, Sanna F, Batetta B. *Role of HDL in Cholesteryl Ester Metabolism of Lipopolysaccharide-Activated P388D1 Macrophages*. J Lipid Res. 2013 Nov; 54(11):3158-69. DOI: <https://doi.org/10.1194/jlr.M042663>
37. Pompei R, Uda S, Piras E, **ANGIUS F**, Batetta B, Ingianni A. *The Human Herpes Virus 8 infection alters lipid synthesis and induces neutral lipid accumulation in primary endothelial cells*. Virologie, 17(2):S1-S304. ISSN: 1267-8694; ISSN (online): 1950-6961
38. Ingianni A, Piras E, Laconi S, **ANGIUS F**, Batetta B, Pompei R. *Latent Herpesvirus 8 infection improves both insulin and glucose uptake in primary endothelial cells*. New Microbiol. 2013 Jul; 36(3):257-65; ISSN: 11217138
39. **ANGIUS F**. *Dati preliminari sulle alterazioni del colesterolo intracellulare nella Malattia di Alzheimer mediante metodi di imaging*. 2012 Jul; ISBN: 9788891021083
40. Uda S, Accossu S, Collu M, Banni S, Sanna F, Vacca C, Murru E, **ANGIUS F**, Mulas C, Diaz G, Spolitu S, Batetta B. *A lipoprotein source of cholesteryl esters is essential for proliferation of CEM-CCRF lymphoblastic cell line*. Tum. Biol. 2011 Dec 10. DOI: <https://doi.org/10.1007/s13277-011-0270-6>
41. Lai ME, Vacquer S, Carta MP, Spiga A, Cocco P, **ANGIUS F**, Mandas A, Dessi S. *Thalassemia intermedia is associated with a proatherogenic biochemical phenotype*. Blood Cells Mol Dis. 2011 Mar 12. DOI: <https://doi.org/10.1016/j.bcmd.2011.02.004>
42. Peiretti E, Mandas A, Cocco P, Norfo C, Abete C, **ANGIUS F**, Pani A, Vascellari S, Del Fiacco G, Diaz G, Dessi S, Fossarello M. *Glucose-6-phosphate-dehydrogenase deficiency as a risk factor for pterygium*. Inv. Ophth. Vis. Sci. 2010 Jun; 51(6):2928-35. DOI: <https://doi.org/10.1167/iovs.09-4426>
43. Cannas C, Musinu A, Ardu A, Orrù F, Peddis D, Casu M, Sanna R, **ANGIUS F**, Diaz G, Piccaluga G. *CoFe₂O₄ and CoFe₂O₄/SiO₂ Core/Shell Nanoparticles: Magnetic and Spectroscopic Study*. Chem Mater. 2010 Apr; 22(11): 3353–61. DOI: <https://doi.org/10.1021/cm903837g>
44. Orrù CD, Cannas MD, Vascellari S, **ANGIUS F**, Cocco PL, Norfo C, Mandas A, La Colla P, Diaz G, Dessi S, Pani A. *In vitro synergistic anti-prion effect of cholesterol ester modulators in combination with chlorpromazine and quinacrine*. Cent. Eur. J. Biol. 2010 Feb; 5(2):151-165. DOI: <https://doi.org/10.2478/s11535-009-0070-9>
45. Orru CD, Cannas MD, Vascellari S, Abete C, Mandas M, **ANGIUS F**, Cocco P, La Colla P, Dessi S, Pani A. *Pharmacologic Cholesterol Homeostasis Affects Prion Generation in a Synergistic Manner*. The Open Conference Proceedings Journal, 2010, 1, 54-60
46. Lai ME, Vacquer S, Carta MP, Spiga A, Cocco PL, **ANGIUS F**, Mandas A, Dessi S. *Chronic hyperplastic anemia as an independent risk factor for atherosclerotic lesions: a lesson from thalassemia intermedia*. Nature Precedings: hdl:10101/npre.2010.4169.1: Posted 26 Jan 2010

47. Pani A, Mandas A, Diaz G, Abete C, Cocco PL, **ANGIUS F**, Brundub A, Muçakab N, Pais ME, Saba A, Barberini L, Zaru C, Palmas M, Putzu PF, Mocali A, Paoletti F, La Colla P, Dessi S. *Accumulation of neutral lipids in peripheral blood mononuclear cells as a distinctive trait of Alzheimer patients and asymptomatic subjects at risk of disease*. BMC Med. 2009 Nov; 7:66. DOI: <https://doi.org/10.1186/1741-7015-7-66>
48. Orrù CD, Cannas MD, Vascellari S, **ANGIUS F**, Cocco PL, Norfo C, Mandas A, La Colla P, Dessi S, Pani A. *In vitro synergistic anti-prion effect of cholesterol ester modulators*. Nature Precedings: hdl:10101/npre.2009.3883.1: Posted 21 Oct 2009
49. Mandas A, Peiretti E, Cocco P, Norfo C, Abete C, **ANGIUS F**, Pani A, Diaz G, Dessi S, Fossarello M. *Glucose-6-phosphate-dehydrogenase deficiency as a risk factor in proliferative disorder development*. Nature Precedings: hdl:10101/npre.2009.3001.1: Posted 29 Mar 2009
50. Pani A, Dessi S, Diaz G, Abete C, Mulas C, Norfo C, **ANGIUS F**, Cannas MD, Orru CD, Mocali A, Cocco PL, La Colla P, Putzu P, Paoletti F. *Altered cholesterol ester cycle in ex vivo skin fibroblasts from Alzheimer patients*. J Alzheimers Dis. 2009 Sep; 18(4):829-41. DOI: <https://doi.org/10.3233/JAD-2009-1193>
51. Diaz G, Melis M, Batetta B, **ANGIUS F**, Falchi AM. *Hydrophobic characterization of intracellular lipids in situ by Nile Red red/yellow emission ratio*. Micron. 2008 Oct; 39(7):819-24. DOI: <https://doi.org/10.1016/j.micron.2008.01.001>
52. Diaz G, Batetta B, Sanna F, Uda S, Reali C, **ANGIUS F**, Melis M, Falchi AM. *Lipid droplet changes in proliferating and quiescent 3T3 fibroblasts*. Histochem Cell Biol. 2008 May; 129(5):611-21 DOI: <https://doi.org/10.1007/s00418-008-0402-2>
53. Fattore L, Spano MS, Altea S, **ANGIUS F**, Fadda P, Fratta W. *Cannabinoid self-administration in rats: sex differences and the influence of ovarian function*. Br J Pharmacol. 2007 Nov; 152(5):795-804. DOI: <https://doi.org/10.1038/sj.bjp.0707465>

ABSTRACT/CONFERENZE

1. Milenkovic S, Ceccarelli M, Scorciapino MA, **ANGIUS F**, Puxeddu S, S. Boi S. *Decoding the MIC-Permeability relationship in Escherichia coli using advanced statistical Machine Learning approaches*. ESCMID Global Apr 11-15, 2025, Wien (AT)
2. **ANGIUS F**, Puxeddu S, Canton S, Scano A, Casti F, Esposito F, Delogu I, Ennas G, Manzin A. *Implementing an effective microbicidal coating to tackle indirect microbial transmission*. SIM Sep 8-11, 2024, Pavia (IT)
3. Delogu I, Puxeddu S, Scano A, Rynkus B, Wojciech S, Canton S, Ennas G, Manzin A, **ANGIUS F**. *Exploring the antibacterial and biocompatibility properties of biodegradable magnesium alloy for orthopedic prosthetic field*. SIM Sep 8-11, 2024, Pavia (IT)
4. Puxeddu S, Canton S, Scano A, Delogu I, De Carolis E, Ennas G, Sanguinetti M, Manzin A, **ANGIUS F**. *Mycocidal efficacy of ozonized oils in different formulation on four different Clade of Candida auris resistant to current therapies*. SIM Sep 8-11, 2024, Pavia (IT)
5. Cabriolu C, Scano A, Mannias G, Puxeddu S, **ANGIUS F**, Ennas G. *Macro-Mesoporous Au-SiO2 Nanocomposites: potential antimicrobial agents*. NG24CHEM SCI Oct 3-4, 2024, Sassari (IT)
6. **ANGIUS F**, Snyderman M, Ho Wai Hung D, Puxeddu S, Delogu I, Pompei R, Manzin A. *Preliminary data on KSHV integration in humans: a potential molecular mechanism for viral-induced oncogenesis?* SIV-ISV Jul 7-9, 2024, Bologna (IT)
7. Puxeddu S, Delogu I, Castangia I, Canton S, Manca ML, Manzin A, **ANGIUS F**. *Antiviral and antioxidant properties of vesicles loaded with an extract obtained from avocado peels*. SIV-ISV Jul 7-9, 2024, Bologna (IT)
8. Scano A, Mannias G, Pilloni M, **ANGIUS F**, Puxeddu S, Castangia I, Hudson S, Ennas, G. *Mechanosynthesis of nanomaterials for biomedical applications. Quo vadis?* XIV INSTM conference, Jun 9-12, 2024. Cagliari (IT)
9. Rynkus B, Simka W, Scano A, Ennas E, Puxeddu S, **ANGIUS F**, Walke W. *The effect of PEO treatment on the properties of biodegradable magnesium alloy WE43*. 6th National Scientific Conference IMPLANTY 2024. May 22-24, 2024, Sotop (PL)
10. Pala G, Melis R, **ANGIUS F**, Manzin A. *Urinary tract infections and G6PD deficiency: review and completion of treatment guidelines*. National Congress AMCLI, Rimini (IT), 8-11 Mar 2024
11. Melis R, Pala G, Puxeddu S, **ANGIUS F**, Manzin A. *A case of multiple dysbiosis: a consequence of unreasoned antibiotic therapy*. National Congress AMCLI, Rimini (IT), 8-11 Mar 2024
12. Depau M, Viridis V, Sacco D, **ANGIUS F**, Di Rosa M, Vacquer S, Canetto A, Manzin A, Marinelli C. *Abiotrophia defectiva, un raro caso di endocardite e pseudoaneurisma dell'aorta: il case report*. National Congress AMCLI, Rimini (IT), 8-11 Mar 2024

13. Puxeddu S, Scano A, Melis R, De Carolis E, Ennas G, Aste A, Sanguinetti M, Manzin A, **ANGIUS F**. *Antimicrobial efficacy of ozonized oils on clinical samples of different Candida strains*. National Congress AMCLI, Rimini (IT), 8-11 Mar 2024
14. **ANGIUS F**, Rodrigues T, Puxeddu S, Delogu I, Pompei R, Pedro JP, Manzin A. *Sulfonamide treatments inhibit gamma-Herpesvirus persistent infection in vivo*. National Congress SIM, Cagliari (IT), 24-27 Sep 2023
15. Puxeddu S, Delogu I, Scano A, Vascellari S, Pala G, Ennas G, Manzin A, **ANGIUS F**. *Ionic liquids as a new effective antimicrobial approach*. National Congress SIM, Cagliari (IT), 24-27 Sep 2023
16. Delogu I, Castangia I, Puxeddu S, Raga E, Manca ML, Manzin A, **ANGIUS F**. *Antimicrobial and antioxidant properties of vesicles loaded with an extract obtained from olive leaves*. National Congress SIM, Cagliari (IT), 24-27 Sep 2023
17. Puxeddu S, Boi S, Scorciapino MA, Ceccarelli M, Milenkovic S, Manzin A, **ANGIUS F**. *Drugs porins-permeability coefficient correlate with the antimicrobial effectiveness*. National Congress SIM, Cagliari (IT), 24-27 Sep 2023
18. Vascellari S, Orrù CD, Zanusso G, Poleggi A, Cardone F, Cossu G, Mandas A, **ANGIUS F**, Puxeddu S, Manzin A, Caughey B. *RT-QuIC detection prion seeding activity in spiked human tears*. National Congress SIM, Cagliari (IT), 24-27 Sep 2023
19. Esposito F, Scano A, **ANGIUS F**, Puxeddu S, Canton S, Tramontano E. *An innovative highly effective microbicidal coating for high-touch surfaces*. National Congress SIMGBM, Cagliari (IT), 22-24 Sep 2023
20. Mocci I, **ANGIUS F**, Ercoli T, Loy F, Palmas MF, Cannas G, Manzin A, Defazio G, Carta AR. *Salivary alpha-synuclein species as diagnostic biomarker for Parkinson's disease*. 20th National Congress SINS, Turin (IT), 14-17 Sep 2023
21. Scano A, **ANGIUS F**, Esposito F, Manzin A, Tramontano E, Ennas G. *A high-effective microbicidal coating to control the indirect microbial transmission*. 10th NRW Nano Conference - Innovations in Materials and Applications, Dortmund (DE), 23-24 May 2023
22. Scano A, **ANGIUS F**, Esposito F, Manzin A, Tramontano E, Ennas G. *Future perspectives to control indirect microbial transmission: a high-effective microbicidal coating*. 30 years of INSTM: past, present and future of the Consortium, Bressanone (BZ), 22-25 Jan 2023
23. **ANGIUS F**, Scano A, Esposito F, Ennas G, Manzin A. *RiV4PoC: A high effective microbicidal coating for high-touch surfaces*. 50th National Congress SIM, Naples (IT), 18-21 Sep 2022
24. Vascellari S, Orrù C, **ANGIUS F**, Carreras PP, Caughey B, Cossu G, Manzin A. *Prion-like a-synuclein detection in ante-mortem intestinal mucosa from Parkinson's disease patients by RT-QuIC*. 50th National Congress SIM, Naples (IT), 18-21 Sep 2022
25. Puxeddu S, Vascellari S, Delogu I, Pala G, Scano A, Ennas G, Manzin A, **ANGIUS F**. *Antimicrobial effectiveness of ozonated olive and sunflower seeds oils*. 50th National Congress SIM, Naples (IT), 18-21 Sep 2022
26. Pala G, Puxeddu S, **ANGIUS F**, Manzin A. *Uncomplicated UTIs and old antimicrobials: a retrospective study on southern Sardinian population*. 50th National Congress SIM, Naples (IT), 18-21 Sep 2022
27. Scorciapino MA, **ANGIUS F**, Manzin A, Piano D, Farci D, Ceccarelli M. *f-PERMEATE: predictive function of drug's permeability coefficient for large database screening*. Workshop, Hamburg, Jul 2022
28. Vascellari S, Palmas V, Serra A, **ANGIUS F**, Sanna G, Madau V, Santoru ML, Melis M, Oppo V, Atzori L, Cossu G, Manzin A. *Distinct gut microbiota and metabolome enterotypes associated with clinical phenotypes of Parkinson's disease*. 48th Virtual National Congress SIM, 16-21 Sep 2021
29. Palmas V, Pisanu S, Madau V, Vascellari S, **ANGIUS F**, Sanna G, Casula E, Deledda A, Loviselli A, Velluzzi F, Manzin A. *Gut microbiota markers associated with extreme longevity in healthy sardinian subjects*. 48th Virtual National Congress SIM, 16-21 Sep 2021
30. Sanna G, Fobofou SAT, Madeddu S, Marongiu A, Serreli G, **ANGIUS F**, Vascellari S, Palmas V, Franke K, Brandt W, Wessjohann LA, Manzin A. *Rare biscoumarin with significant anti-HIV-1 activity*. 48th Virtual National Congress SIM, 16-21 Sep 2021
31. **ANGIUS F**, Porotto M. *Characterization of a measles virus neutralizing monoclonal antibody targeting specific conformation of fusion protein*. 48th Virtual National Congress SIM, 21-22 Sep 2020
32. **ANGIUS F**, Porotto M. *Functional analysis of a SSPE virus indicates that hyperfusogenic fusion protein contributes to measles virus infection in the brain*. 47th National Congress SIM, Rome (IT), 18-21 Sep 2019
33. Ingianni A, Incani A, Pompei R, Deiana M, **ANGIUS F**. *Human Herpesvirus 8 infection contributes to ROS production in diabetes type 2 patients*. 47th National Congress SIM, Rome (IT), 18-21 Sep 2019
34. Ferren M, **ANGIUS F**, Smuts H, Rybkina K, Stelitano D, Mathieu C, Moscona A, Horvat B, Hashiguchi T, Porotto M, Hardie D. *Analysis of a subacute sclerosing panencephalitis (SSPE) virus shows*

- hyperfusogenic F protein contributes to measles virus infection in the brain.* 38th Annual Meeting ASV, Minneapolis (US), 20-24 Jul 2019
35. **ANGIUS F**, Stelitano D, Porotto M. *Measles virus and CNS adaptation.* **FEMS Travel Grant.** 46th National Congress SIM, Palermo (IT), 26-29 Sep 2018
 36. Pompei R, **ANGIUS F**. *Malattie infettive e malattie metaboliche: un rapporto casuale o causale?* 12nd National Congress SIMiF, Camerino (IT), 21-22 Jun 2018
 37. **ANGIUS F**, Porotto M. *Measles CNS infection and its inhibition.* **Best Poster Prize in Virology** Mario Campa Foundation. 45th National Congress SIM, Genoa (IT), 27-30 Sep 2017
 38. Marras L, **ANGIUS F**, Piras E, Ingianni A, Bigi R, Dittmer D, Pompei R. *Inhibition of Human Herpesvirus 8 by Sulfone Derivatives.* 45th National Congress SIM, Genoa (IT), 27-30 Sep 2017
 39. Marras L, **ANGIUS F**, Piras E, Uda S, Madeddu C, Serpe R, Pompei R, Ingianni A. *Antimicrobial sulfonamides inhibit Herpesvirus 8 latency by impairing the MDM2-p53 complex formation.* 44th National Congress SIM, Pisa (IT), 25-28 Sep 2016
 40. **ANGIUS F**, Pompei R. **Invited lecture:** *Herpesvirus 8 infection and cellular metabolism alterations.* 43rd National Congress SIM, Naples (IT), 27-30 Sep 2015
 41. **ANGIUS F**, Piras E, Uda S, Madeddu C, Serpe R, Ingianni A, Pompei R. *Sulfonamide compounds inhibit latent Human Herpesvirus 8 replication by interfering with MDM2-p53 complex formation.* 43rd National Congress SIM, Naples (IT), 27-30 Sep 2015
 42. **ANGIUS F**, Spolitu S, Uda S, Frau A, Deligia S, Lacko A, Sabnis N, Batetta B. *Role of P-gp in controlling of metabolism in MDR1 cells: HDL as new delivery strategy for anticancer drugs.* Riunione Scientifica Scuola Mario Umberto Dianzani, Cagliari (IT), 20-21 Mar 2015
 43. **ANGIUS F**, Uda S, Piras E, Spolitu S, Ingianni A, Batetta B, Pompei R. *Lipidi neutri e angiogenesi in cellule primarie umane infettate con virus Herpes 8.* 41st National Congress SIM, Riccione (IT), 13-16 Oct 2013
 44. Pompei R, Uda S, Piras E, **ANGIUS F**, Batetta B, Ingianni A. *The Human Herpes Virus 8 infection alters lipid synthesis and induces neutral lipid accumulation in primary endothelial cells.* *Virologie*, 17(2):S1-S304. ISSN: 1267-8694. 5th European Congress Virology. Lyon (FR), 11-13 Sep 2013
 45. Marongiu F, Serra MP, Sini M, Marongiu M, **ANGIUS F**, Laconi E. *Cell transplantation modulates the liver microenvironment and delays the emergence of hepatocellular carcinoma.* 12th Congress of the Cell Transplant Society, Milan (IT), 7-11 July 2013
 46. **ANGIUS F**, Uda S, Spolitu S, Deligia S, Accossu S, Frau A, Batetta B. *Inhibition of cholesterol esterification increases cholesteryl ester uptake from HDL in parental and MDR1 resistant CCRF-CEM cells.* European Association for Cancer Research (EACR), the American Association for Cancer Research (AACR), and the Italian Cancer Society (SIC) Special Conference, Florence (IT), 20-23 June 2014
 47. Marongiu F, Serra MP, Sini M, Marongiu M, **ANGIUS F**, Laconi E. *Modulating the liver microenvironment delays the emergence of hepatocellular carcinoma.* 48th Annual meeting of the European Association for the Study of the Liver (EASL), The International Liver Congress, Amsterdam (NE), 24-28 Apr 2013
 48. Uda S, Spolitu S, Accossu S, **ANGIUS F**, Collu M, Batetta B. *Possible role of P-glycoprotein MDR1 in controlling cancer cell esterification by modulating cholesteryl ester uptake from HDL.* Cell Symposia - Angiogenesis, Metabolic Regulation, and Cancer Biology in association with VIB, Leuven (BE), 6-8 Jul 2012
 49. Piras E, Laconi S, **ANGIUS F**, Batetta B, Pompei R, Ingianni A. *Alterazioni metaboliche in cellule primarie endoteliali indotte da Herpes virus 8 in fase latente.* 9th National Congress SIMiF, Ferrara (IT), 15-16 Jun 2012
 50. **ANGIUS F**, Uda S, Spolitu S, Accossu S, Diaz G. *Neutral lipids accumulation in peripheral blood mononuclear cells: hallmark of Alzheimer's Disease?* 6th World Congress on Controversies in Neurology (CONy), Wien (AT), 8-11 Mar 2012
 51. Spolitu S, Uda S, Accossu S, Diaz G, **ANGIUS F**. *Alteration of intracellular cholesterol in skin fibroblasts from Alzheimer's Disease patients.* 6th World Congress on Controversies in Neurology (CONy), Wien (AT), 8-11 Mar 2012
 52. Floris A, Marongiu F, Fadda AM, Scano A, Quintela MAL, **ANGIUS F**, Diaz G, Ennas G, Sinico C. A *Preparation, characterization and cytotoxicity studies of liposome-hydrophobic magnetite hybrid colloids.* ILS 2011 meeting - Liposome advances: Progress in drug and vaccine delivery, London (UK) 2011
 53. Uda S, Spolitu S, Accossu S, Diaz G, Batetta B and **ANGIUS F**. *Inhibition of cholesterol esterification influences cholesterol metabolism and inflammatory response in lipopolysaccharide-activated P388D1 macrophages.* 9th International Congress of Coronary Artery Disease (ICCAD), Venice (IT), 23-26 Oct 2011
 54. Spolitu S, **ANGIUS F**, Accossu S, Diaz G, Batetta B and Uda S. *A source of cholesteryl esters (CEs) is essential for an efficient antimicrobial response in lipopolysaccharide-activated P388D1 macrophages.* 9th International Congress of Coronary Artery Disease (ICCAD), Venice (IT), 23-26 Oct 2011

55. Pani A, Orru C, Cannas M, Vascellari S, Abete C, **ANGIUS F**, Cocco PL, Norfo C, Mandas A, La Colla P, Dessi S. *Lipid derangement and prion misfolding in prion infected mouse neuroblastoma cells lines and in brains and skin fibroblasts from scrapie-susceptible sheep*. 14th European Congress of Virology. Cernobbio (IT), 7-11 Apr. 2010
56. Orru CD, Cannas MD, Vascellari S., Abete C, **ANGIUS F**, Cocco PL, Norfo C, Mandas A, La Colla P, Dessi S, Pani A. *Pharmacologic-induced cholesterol homeostasis affects prion generation in a synergistic manner*. 2nd International conference on drug discovery and therapy, Dubai (UAE), 1-4 Feb 2010
57. **ANGIUS F** and Mulas C. *Dati preliminari sulle alterazioni del colesterolo intracellulare nella Malattia di Alzheimer*. Dissemination of scientific research in medicine, Cagliari (IT), 18 Jun 2010
58. Cannas MD, Orru C, Vascellari S, Abete C, **ANGIUS F**, Cocco PL, Norfo C, La Colla P, Dessi S, Pani A. *Cholesterol homeostasis and prion misfolding: a comparative study in mouse neuroblastoma cells and in sheep brains and skin fibroblasts*. 11th FISV congress, Riva del Garda (IT), 23-25 Sept 2009
59. Cocco PL, **ANGIUS F**, Abete C, Mulas C, Demuro G, Borgia A, Vacquer S, Carta MP, Dessi S, Diaz G, Lai ME. *Complicanze cardiovascolari nei B-talassemici intermedi: coinvolgimento del colesterolo e del metabolismo del ferro*. Dissemination of scientific research in medicine, Cagliari (IT), 29 Jun 2009
60. Mandas A, Pani A, Diaz G, Abete C, Cocco PL, **ANGIUS F**, Brundu A, Muçaka N, Pais ME, Saba A, Barberini L, Zaru C, Palmas M, Putzu PF, Mocali A, Paoletti F, La Colla P, Dessi S. *Accumulo citoplasmatico di lipidi neutri in linfomonociti periferici: biomarker preclinico di malattia di Alzheimer?* 54th National Congress SIGG, Firenze (IT), 2-5 Dec 2009
61. Cocco PL, **ANGIUS F**, Abete C, Mulas C, Demuro G, Borgia A, Vacquer S, Carta P, Dessi S, Lai E. *Cardiovascular disease in β -thalassemia intermedia: involvement of cholesterol and iron metabolism*. **Best Poster Prize**, 5th National Congress SoSTE, Cagliari (IT), 16-18 Oct 2008
62. **ANGIUS F**, Cocco PL, Zaru C, Palmas M, Abete C, Mulas C, Paoletti F, Putzu P, Diaz G, Dessi S. *Ruolo del metabolismo lipidico nella malattia di Alzheimer: aspetti citomorfologici in cellule periferiche*. 53rd National Congress SIGG, Firenze (IT), 26-29 Nov 2008
63. Cocco PL, **ANGIUS F**, Zaru C, Palmas M, Abete C, Mulas C, Paoletti F, Diaz G, Dessi S. *Ruolo del metabolismo lipidico nella malattia di Alzheimer: aspetti molecolari in fibroblasti cutanei e linfomonociti*. 53rd National Congress SIGG, Firenze (IT), 26-29 Nov 2008
64. Zaru C, Palmas M, Abete C, Mulas C, Cocco P, **ANGIUS F**, Pani A, Dessi S, Diaz G, Putzu P. *Possibile nuovo bio-marker diagnostico di malattia di Alzheimer: gli esteri del colesterolo*. 53rd National Congress SIGG, Firenze (IT), 26-29 Nov 2008
65. Palmas M, Zaru C, Abete C, Mulas C, Cocco P, **ANGIUS F**, Pani A, Dessi S, Diaz G, Putzu P. *Variazioni del metabolismo lipidico in linfomonociti periferici (PBMCS): possibile bio-marker predittivo di malattia di Alzheimer in familiari di pazienti affetti*. Giornale di Gerontologia 2008 Oct; 56 (5): 521, 53rd National Congress SIGG, Firenze (IT), 26-29 Nov 2008
66. Melis M, Diaz G, **ANGIUS F** and Falchi AM. *Nile Red Ratiometric method for the study of cell lipids*. 61st National Congress SIAI, Sassari (IT), 19-22 Sep 2007
67. Diaz G, Falchi AM, Melis M, **ANGIUS F**, Angius R, Angius R, Monduzzi M. *Interazioni tra nanostrutture lipidiche disperse e fibroblasti 3T3*. 6th CSGI, Ascoli Piceno (IT), 20-21 Sep 2007
68. Spano M, Fattore L, Altea S, **ANGIUS F**, Fadda P and Fratta W. *Cannabinoid self-administration in the rat: effect of ovariectomy and Gender Differences*. 33rd National Congress SIF, Cagliari (IT), 6-9 Jun 2007

Cagliari, 13/03/2025

Prof Fabrizio Angius, PhD